Targeting Small Molecules and Peptides to the p66-p51 Reverse Transcriptase Interface

摘要: Thirty years after the discovery of human immunodeficiency virus (HIV) (Sepkowitz 2001), causative agent acquired syndrome (HIV/AIDS), and successful development approval antiretroviral drugs, no curative treatment is available (Simon et al. 2006; Saliba Yeni Sarafianos 2004). Therefore, there remains an urgent need for new less toxic drugs that are either active against emerging drug-resistant viruses or directed to novel targets in replication cycle, which may complement multidrug combinations. A better understanding individual steps viral cycle dynamics during infection has provided major breakthroughs a wide spectrum antiviral strategies (Sarafianos 2004; Camarasa 2006). Recently, order offer perspectives design inhibitors, extensive efforts have been made synthesis molecules target interface multi-subunit proteins required entry, replication, maturation (Camarasa Divita 1994; Mori 2011; Esposito 2012; Warrilow 2009).